M-mode echocardiographic evaluation of systolic function, LV volume and mass in children on growth hormone therapy

Citation
L. Stamoyannou et al., M-mode echocardiographic evaluation of systolic function, LV volume and mass in children on growth hormone therapy, J PED END M, 13(2), 2000, pp. 157-161
Citations number
18
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
ISSN journal
0334018X → ACNP
Volume
13
Issue
2
Year of publication
2000
Pages
157 - 161
Database
ISI
SICI code
0334-018X(200002)13:2<157:MEEOSF>2.0.ZU;2-H
Abstract
Since abnormal endogenous growth hormone (GH) secretion in adults is associ ated with cardiac dysfunction, it is important to ensure that GH therapy in children and adolescents does not cause similar effects, Forty-two growth hormone-deficient children (Group 1) (19 girls, 23 boys) were evaluated. Si x girls and seven boys were prepubertal with a mean age of 6.65 yr (range 4 .37-9.73 yr), Twenty-nine were pubertal (13 girls, 16 boys), mean age 13.57 yr (range 10.08-16.76 yr), The patients had been on long-term GH therapy f or 34.97 +/- 18.78 months with an average weekly dose of 17.61 IU/m(2)/wk. The mean height SDS was -2.85 +/- 1.22 for boys and -2.5 +/- 0.64 for girls at the onset of therapy, and at the time of examination -1.8 +/- 1.32 for the boys and 1.87 +/- 0.94 for the girls. Thirty-four normal control subjec ts (Group 2) matched for age, sex and body size were also studied. Left ven tricular volume (LV), mass and systolic function [shortening fraction (FS)] were evaluated by two-dimensional guided M-mode echocardiography, Blood pr essure was also measured. No differences in blood pressure were observed be tween patients and controls. There was no correlation of GH dose and durati on of therapy with LV measurements. No significant differences were found b etween Group 1 and Group 2, These observations suggest that long term admin istration of GH does not produce adverse cardiac effects in GH deficient ch ildren, Nevertheless, longer follow-up studies are still needed to confirm the safety of long-term rhGH treatment.